Linked Life Data

17131118

Source:http://linkedlifedata.com/resource/pubmed/id/17131118

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17131118rdf:typepubmed:Citationlld:pubmed
pubmed-article:17131118lifeskim:mentionsumls-concept:C1261468lld:lifeskim
pubmed-article:17131118lifeskim:mentionsumls-concept:C0020205lld:lifeskim
pubmed-article:17131118lifeskim:mentionsumls-concept:C0597032lld:lifeskim
pubmed-article:17131118lifeskim:mentionsumls-concept:C0338106lld:lifeskim
pubmed-article:17131118lifeskim:mentionsumls-concept:C0011306lld:lifeskim
pubmed-article:17131118lifeskim:mentionsumls-concept:C1282910lld:lifeskim
pubmed-article:17131118lifeskim:mentionsumls-concept:C0431085lld:lifeskim
pubmed-article:17131118lifeskim:mentionsumls-concept:C0042196lld:lifeskim
pubmed-article:17131118lifeskim:mentionsumls-concept:C1545588lld:lifeskim
pubmed-article:17131118lifeskim:mentionsumls-concept:C1515895lld:lifeskim
pubmed-article:17131118lifeskim:mentionsumls-concept:C2348767lld:lifeskim
pubmed-article:17131118lifeskim:mentionsumls-concept:C0591833lld:lifeskim
pubmed-article:17131118pubmed:issue7lld:pubmed
pubmed-article:17131118pubmed:dateCreated2007-4-26lld:pubmed
pubmed-article:17131118pubmed:abstractTextCancer immunotherapy by dendritic cell (DC)/tumor cell fusion hybrids (DC/TC hybrids) has been shown to elicit potent anti-tumor effects via the induction of immune responses against multiple tumor-associated antigens. In the present study, we compared the anti-tumor effects of vaccinating Balb/c mice (H-2(d)) with CT26CL25 colon carcinoma cells that had been fused with either syngeneic DCs from Balb/c mice, allogeneic DCs from C57BL/6 mice (H-2(b)) or semiallogeneic DCs from B6D2F1 mice (H-2(b/d)). Preimmunization with either semiallogeneic or allogeneic DC/TC hybrids induced complete protection from tumor challenge, whereas mice preimmunized with syngeneic DC/TC hybrids were only partially protected (75% tumor rejection). The average number of pulmonary metastases after intravenous tumor injection decreased significantly following immunization with semiallogeneic or allogeneic DC/TC hybrids (8.3 +/- 7.9 or 16.3 +/- 3.5, mean +/- SD) relative to syngeneic DC/TC hybrids (67.8 +/- 6.3). These data demonstrate that vaccination with semiallogeneic DC/TC hybrids resulted in the greatest anti-tumor efficacy. Anti-tumor effects showed by in vivo studies were virtually accomplished by the frequency of induced CTLs specific to both gp70 and beta-galactosidase assessed by using pentameric assay. Among the fusion vaccines tested, semiallogeneic DC/TC hybrids induced the highest ratio of Th1 cytokine IFN-gamma to Th2 cytokine IL-10. In addition, allogeneic or semiallogeneic DC/TC hybrids elicited a significantly stronger NK activity than syngeneic DC/TC hybrids. These findings suggest that in clinical settings, DCs derived from a healthy donor (which are generally characterized as more semiallogeneic than allogeneic) may be more capable than autologous DCs of inducing promising anti-tumor effects in vaccinations with DC/TC hybrids.lld:pubmed
pubmed-article:17131118pubmed:languageenglld:pubmed
pubmed-article:17131118pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17131118pubmed:citationSubsetIMlld:pubmed
pubmed-article:17131118pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17131118pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17131118pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17131118pubmed:statusMEDLINElld:pubmed
pubmed-article:17131118pubmed:monthJullld:pubmed
pubmed-article:17131118pubmed:issn0340-7004lld:pubmed
pubmed-article:17131118pubmed:authorpubmed-author:KamigakiTakas...lld:pubmed
pubmed-article:17131118pubmed:authorpubmed-author:KurodaYoshika...lld:pubmed
pubmed-article:17131118pubmed:authorpubmed-author:AjikiTetsuoTlld:pubmed
pubmed-article:17131118pubmed:authorpubmed-author:NakamuraTetsu...lld:pubmed
pubmed-article:17131118pubmed:authorpubmed-author:YamamotoMasas...lld:pubmed
pubmed-article:17131118pubmed:authorpubmed-author:KimYongsikYlld:pubmed
pubmed-article:17131118pubmed:authorpubmed-author:KurodaDaisuke...lld:pubmed
pubmed-article:17131118pubmed:authorpubmed-author:YasudaTakashi...lld:pubmed
pubmed-article:17131118pubmed:authorpubmed-author:KawasakiKenta...lld:pubmed
pubmed-article:17131118pubmed:authorpubmed-author:TakaseShiroSlld:pubmed
pubmed-article:17131118pubmed:authorpubmed-author:KanemitsuKiyo...lld:pubmed
pubmed-article:17131118pubmed:issnTypePrintlld:pubmed
pubmed-article:17131118pubmed:volume56lld:pubmed
pubmed-article:17131118pubmed:ownerNLMlld:pubmed
pubmed-article:17131118pubmed:authorsCompleteYlld:pubmed
pubmed-article:17131118pubmed:pagination1025-36lld:pubmed
pubmed-article:17131118pubmed:meshHeadingpubmed-meshheading:17131118...lld:pubmed
pubmed-article:17131118pubmed:meshHeadingpubmed-meshheading:17131118...lld:pubmed
pubmed-article:17131118pubmed:meshHeadingpubmed-meshheading:17131118...lld:pubmed
pubmed-article:17131118pubmed:meshHeadingpubmed-meshheading:17131118...lld:pubmed
pubmed-article:17131118pubmed:meshHeadingpubmed-meshheading:17131118...lld:pubmed
pubmed-article:17131118pubmed:meshHeadingpubmed-meshheading:17131118...lld:pubmed
pubmed-article:17131118pubmed:meshHeadingpubmed-meshheading:17131118...lld:pubmed
pubmed-article:17131118pubmed:meshHeadingpubmed-meshheading:17131118...lld:pubmed
pubmed-article:17131118pubmed:meshHeadingpubmed-meshheading:17131118...lld:pubmed
pubmed-article:17131118pubmed:meshHeadingpubmed-meshheading:17131118...lld:pubmed
pubmed-article:17131118pubmed:meshHeadingpubmed-meshheading:17131118...lld:pubmed
pubmed-article:17131118pubmed:meshHeadingpubmed-meshheading:17131118...lld:pubmed
pubmed-article:17131118pubmed:meshHeadingpubmed-meshheading:17131118...lld:pubmed
pubmed-article:17131118pubmed:meshHeadingpubmed-meshheading:17131118...lld:pubmed
pubmed-article:17131118pubmed:year2007lld:pubmed
pubmed-article:17131118pubmed:articleTitleSuperior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma.lld:pubmed
pubmed-article:17131118pubmed:affiliationDepartment of Gastroenterological Surgery, Graduate School of Medical Sciences, Kobe University, Kusunoki-cho 7-5-1, Chuo-ku, Kobe 650-0017, Japan. yasudatyamane@yahoo.co.jplld:pubmed
pubmed-article:17131118pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17131118pubmed:publicationTypeComparative Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17131118lld:pubmed